Oral GLP-1 drugs may dampen brain rewards, widening use beyond dieting

NIH-funded Nature study shows oral small-molecule GLP-1 weight-loss drugs can access a deep-brain reward circuit, activating the central amygdala and reducing dopamine release during pleasure-driven eating, potentially dampening hedonic cravings beyond hunger and hinting at uses in addiction; further research is needed to confirm effects in humans and across substances as access to these meds grows.